The new changes to the “Sunshine Act” has left people more confused than ever in regard to information needing to be submitted, what payments are supposed to be submitted and the entire reporting format. Andy McNeill, (AMI, CEO) who has a wealth of experience in the pharmaceutical meeting planning industry, with clients such as Baxter, Pfizer and Roche, elaborates on the changes and how they will affect meeting planners in the future.
Shining a Light on Rare Diseases
Inside Greater Honeycomb's Mission to Support Overlooked Patients For millions of people living with rare diseases,...
